Navigation Links
LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
Date:9/18/2007

BOZEMAN, Mont., Sept. 18 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., today announced a strategic partnership with Biogen Idec (Nasdaq: BIIB) to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases including potential respiratory, gastrointestinal, and autoimmune indications. CD103 is the unique alphaE-beta7 integrin that has been implicated in the activation, homing and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs.

Under terms of the agreement, LigoCyte will receive milestone payments on the successful development of drug candidates. The collaboration includes an opportunity for co-development, co-promotion, and sharing of profits resulting from commercialized products.

"We are very pleased to be entering into this collaboration with Biogen Idec for the development of our lead anti-inflammatory therapy," said Donald P. Beeman, CEO and chairman of the board for LigoCyte. "This strategic alliance confirms the value of LigoCyte's immunology expertise."

About LigoCyte

LigoCyte Pharmaceuticals, Inc., is a privately held biopharmaceutical company developing vaccines and therapeutic monoclonal antibodies focused on important respiratory and gastrointestinal markets. The company is currently investigating its norovirus vaccine in human clinical studies. For more information on LigoCyte, please visit http://www.ligocyte.com.


'/>"/>
SOURCE LigoCyte Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and PITTSBURGH , ... MYL ) today announced that its shareholders have ... (NYSE: PRGO ; TASE) and the related ... at an extraordinary general meeting of shareholders held ... votes cast at the extraordinary general meeting. In ...
(Date:8/28/2015)... 2015 The report "Eubiotics Market by Type (Probiotics, ... and Aquaculture), & by Region ( North America ... , and Rest of the World) - Global Trends and ... Eubiotics was valued at USD 4.62 Billion in 2014 and ... a CAGR of 7.4% from 2015 to 2020. ...
(Date:8/28/2015)... and LONDON , August 28, 2015 /PRNewswire/ ... approach seamlessly connects people, technologies and ... improving outcomes and the cost of healthcare ... AEX: PHIA) today announced its presence at  ESC Congress 2015 ... including Heart Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... SAN DIEGO, April 11, 2011 Awarepoint Corporation ... Awareness and Real-time Location System (RTLS) at Booth #901 ... 44th Annual Meeting and Exposition , which will be ... Center. Awarepoint,s live demo will highlight how nurses can ...
... Ill., April 11, 2011 PharMEDium Healthcare Corporation has ... Anesthesiologists (ASA), as a part of a new Corporate ... management companies. David N. Jonas, PharMEDium Chairman ... efforts to advance the anesthesiology field through leadership, education ...
Cached Medicine Technology:Awarepoint to Showcase Industry-leading Real-time Location System (RTLS) at AONE Annual Meeting 2PharMEDium Becomes a Corporate Supporter of the American Society of Anesthesiologists (ASA) 2
(Date:8/30/2015)... ... August 30, 2015 , ... Natural Rest contains a unique ... sleep aids and calming remedies, which help to improve mood disorders and anxiety. Like ... deal of research in the field of regenerative medicine conducted by Dr. Amit Patel ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare ... for the treatment of prostate cancer, has announced the roll-out of its newest ... treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is a ... field in the military. All too often VA hospitals treat patients with harmful and ... the VA program over a decade ago, the reality is that only 10% of ...
(Date:8/29/2015)... ... 29, 2015 , ... People who have heart or lung ... asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with ... problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... causing strokes in young people, though the condition's progress can ... ,The disorder known as Fabry disease is characterised by ... nodular skin lesions and progressive renal insufficiency. ,It ... the body to process oils, waxes and fatty acids, reports ...
... centres in Singapore and India plan to expand joint ... cancer centre said Tuesday//. ,The cooperation between Singapore's ... Centre builds on a screening programme credited with cutting ... the Indian state by 40 percent. ,The ...
... a scene of pandemonium with protesting students on the ... on the other, causing apparent commotion amongst patients. The ... behind these protests. ,Patients have expressed consolation at ... Chandra Majumdar said “Normally, I have to wait for ...
... anti-cancer effects of exercise results from an increase in ... cell growth and cause cell death. ,A ... protein that inhibits the action of another protein called ... cell growth, due to which the result appears. ...
... According to the doctors at Queen’s Medical Centre, Nottingham it ... halt their growth//. Thalidomide created so much commotion when it ... caused horrific birth defects in 12,000 babies. The babies were ... from the market and is now unlicensed in the UK. ...
... According to a research it was found that radiotherapy given ... against breast cancer//. The researchers from UK and US said ... the recurrence of cancer when compared to the conventional regime ... of the 10-year trial which was funded by the Cancer ...
Cached Medicine News:Health News:Rare Genetic Disorder Could Cause Strokes In Young People 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: